Should gastroenterologists prescribe cannabis? The highs, the lows and the unknowns

被引:2
|
作者
Samuel, Sonia [1 ]
Michael, Mark [1 ]
Tadros, Micheal [2 ]
机构
[1] Albany Med Ctr, Dept Internal Med, Albany, NY 12208 USA
[2] Albany Med Ctr, Dept Gastroenterol & Hepatol, 43 New Scotland Ave, Albany, NY 12208 USA
关键词
Marijuana; cannabis; Endocannabinoid system; Side effects; Gastrointestinal disorders; ESOPHAGEAL SPHINCTER RELAXATIONS; INDUCED ACUTE-PANCREATITIS; IRRITABLE-BOWEL-SYNDROME; BODY-MASS INDEX; CROHNS-DISEASE; DOUBLE-BLIND; MARIJUANA USE; COMBINATION THERAPY; ANXIETY DISORDERS; MEGESTROL-ACETATE;
D O I
10.12998/wjcc.v11.i18.4210
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cannabis, commonly known as marijuana, is a drug extracted from the Cannabis plant known for its psychotropic and medicinal properties. It has been used for healing purposes during ancient times, although its psychoactive components led to its restricted use in medicine. Nonetheless, cannabis is found to have modulatory effects on the endocannabinoid system exhibiting its medicinal role in the gastrointestinal (GI) system. Emerging animal and human studies demonstrate the influential effects of cannabis on a variety of GI diseases including inflammatory bowel disease, motility disorders and GI malignancies. It also has a regulatory role in GI symptoms including nausea and vomiting, anorexia, weight gain, abdominal pain, among others. However, both its acute and chronic use can lead to undesirable side effects such as dependency and addiction, cognitive impairment and cannabinoid hyperemesis syndrome. We will discuss the role of cannabis in the GI system as well as dosing strategies to help guide gastroenterologists to assess its efficacy and provide patient counseling before prescription of medical marijuana.
引用
收藏
页数:22
相关论文
共 47 条
  • [41] THE COMMERCIAL FOCUS OF US CANNABIS REGULATION MODELS SHOULD NOT CLOSE OUR EYES TO OTHER OPTIONS
    Rolles, Steve
    Murkin, George
    ADDICTION, 2016, 111 (12) : 2092 - 2094
  • [42] Should cannabis self-cultivation be part of a public health-oriented legalization policy framework?
    Fischer, Benedikt
    Robinson, Tessa
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2024, 115 (05): : 784 - 788
  • [43] Psychiatric Disorders and Comorbid Cannabis Use: When Should We Be Concerned and What Can We Do About It?
    Satre, Derek D.
    Borsari, Brian
    Tompkins, D. Andrew
    Ramo, Danielle
    JOURNAL OF CLINICAL PSYCHIATRY, 2018, 79 (06)
  • [44] Cannabis: The never-ending, nefarious nepenthe of the 21st century: What should the clinician know?
    Greydanus, Donald E.
    Kaplan, Gabriel
    Baxter, Louis E., Sr.
    Patel, Dilip R.
    Feucht, Cynthia L.
    DM DISEASE-A-MONTH, 2015, 61 (04): : 118 - 175
  • [45] Causal relationship between cannabis use and psychotic symptoms or depression.: Should we wait and see?: A public health perspective
    de Irala, J
    Ruiz-Canela, M
    Martínez-González, MA
    MEDICAL SCIENCE MONITOR, 2005, 11 (12): : RA355 - RA358
  • [46] How ideology shapes the evidence and the policy: what do we know about cannabis use and what should we do?
    Macleod, John
    Hickman, Matthew
    ADDICTION, 2010, 105 (08) : 1326 - 1330
  • [47] "Should I Inhale?"-Perceptions, Barriers, and Drivers for Medicinal Cannabis Use amongst Australian Women with Primary Dysmenorrhoea: A Qualitative Study
    Sinclair, Justin
    Armour, Susanne
    Akowuah, Jones Asafo
    Proudfoot, Andrew
    Armour, Mike
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (03)